Wedoany.com Report-Apr. 11, Asahi Kasei has launched Asahi Kasei Life Science, a new division dedicated to its bioprocess operations, to address the rising needs of the pharmaceutical industry. This restructuring, effective from April 1, 2025, enables the company to deliver more efficient services, advance bioprocess innovation, and enhance support for emerging therapeutic approaches.
Ken Shinomiya, President of Asahi Kasei Life Science.
The new entity consolidates Asahi Kasei’s bioprocess-related units, including virus removal filters like Planova and Microfilters Biooptimal, as well as specialized services from its acquired organizations. These include Virusure in Austria, acquired in 2019 for contract research testing; Bionique Testing Laboratories in the U.S., acquired in 2021; and Bionova Scientific, a U.S.-based biologics contract development and manufacturing organization, acquired in 2022. This integrated structure strengthens Asahi Kasei’s ability to serve the complex pharmaceutical supply chain.
Asahi Kasei Life Science offers a comprehensive portfolio of bioprocess solutions. Its Planova virus removal filters and related equipment enhance the safety and efficiency of producing biotherapeutic products, such as antibody drugs, plasma derivatives, and nucleic acid therapies. Newly introduced products, including Planova FG1 and Thesys SCS and ACS Columns, have gained strong recognition among industry partners for their reliability and performance.
To support the growing global demand, Asahi Kasei has expanded its infrastructure. In 2023, the company upgraded its facility in Glenview, Illinois, to advance innovation in fluid management equipment and virus filtration technology. In 2024, a new assembly plant for Planova was completed in Nobeoka, Miyazaki, Japan, ensuring a stable supply of critical bioprocess components.
Additionally, Asahi Kasei has ventured into the plasmid DNA (pDNA) market through Bionova, with plans to establish a new pDNA facility in Texas. This initiative aims to support emerging fields like cell and gene therapy, fostering growth in innovative treatment modalities. The company remains committed to investing in these areas to drive progress and maintain its leadership in bioprocess solutions.
Ken Shinomiya, President of Asahi Kasei Life Science, stated: “I am thrilled to announce the start of operations at Asahi Kasei Life Science, which began on April 1. Focused on the field of life science centered on the bioprocess business, we aim to expand as part of the growing Healthcare sector business, the main growth driver of the Asahi Kasei Group. We will contribute to the advancement of the pharmaceutical industry as a premium partner that provides innovative and reliable products and services.”
By aligning its expertise and resources, Asahi Kasei Life Science is well-positioned to meet the evolving needs of pharmaceutical companies, supporting the development and production of advanced therapies worldwide.
